Inhibition of Cpeb3 ribozyme elevates CPEB3 protein expression and polyadenylation of its target mRNAs, and enhances object location memory

  1. Claire C Chen
  2. Joseph Han
  3. Carlene A Chinn
  4. Jacob S Rounds
  5. Xiang Li
  6. Mehran Nikan
  7. Marie Myszka
  8. Liqi Tong
  9. Luiz F M Passalacqua
  10. Timothy Bredy
  11. Marcelo A Wood  Is a corresponding author
  12. Andrej Luptak  Is a corresponding author
  1. University of California, Irvine, United States
  2. University of Queensland, Australia
  3. Ionis Pharmaceuticals, United States

Abstract

A self-cleaving ribozyme that maps to an intron of the cytoplasmic polyadenylation element binding protein 3 (Cpeb3) gene is thought to play a role in human episodic memory, but the underlying mechanisms mediating this effect are not known. We tested the activity of the murine sequence and found that the ribozyme’s self-scission half-life matches the time it takes an RNA polymerase to reach the immediate downstream exon, suggesting that the ribozyme-dependent intron cleavage is tuned to co-transcriptional splicing of the Cpeb3 mRNA. Our studies also reveal that the murine ribozyme modulates maturation of its harboring mRNA in both cultured cortical neurons and the hippocampus: inhibition of the ribozyme using an antisense oligonucleotide leads to increased CPEB3 protein expression, which enhances polyadenylation and translation of localized plasticity-related target mRNAs, and subsequently strengthens hippocampal-dependent long-term memory. These findings reveal a previously unknown role for self-cleaving ribozyme activity in regulating experience-induced co-transcriptional and local translational processes required for learning and memory.

Data availability

All data generated or analyzed during this study are included in the manuscript and supporting file; Source Data files have been provided for Figures 1 - 7.

Article and author information

Author details

  1. Claire C Chen

    Department of Pharmaceutical Sciences, University of California, Irvine, Irvine, United States
    Competing interests
    No competing interests declared.
  2. Joseph Han

    Department of Neurobiology and Behavior, University of California, Irvine, Irvine, United States
    Competing interests
    No competing interests declared.
  3. Carlene A Chinn

    Department of Neurobiology and Behavior, University of California, Irvine, Irvine, United States
    Competing interests
    No competing interests declared.
  4. Jacob S Rounds

    Department of Neurobiology and Behavior, University of California, Irvine, Irvine, United States
    Competing interests
    No competing interests declared.
  5. Xiang Li

    Queensland Brain Institute, University of Queensland, Brisbane, Australia
    Competing interests
    No competing interests declared.
  6. Mehran Nikan

    Ionis Pharmaceuticals, Carlsbad, United States
    Competing interests
    Mehran Nikan, Mehran Nikan is affiliated with Ionis Pharmaceuticals. The author has no financial interests to declare..
  7. Marie Myszka

    Department of Chemistry, University of California, Irvine, Irvine, United States
    Competing interests
    No competing interests declared.
  8. Liqi Tong

    Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, United States
    Competing interests
    No competing interests declared.
  9. Luiz F M Passalacqua

    Department of Pharmaceutical Sciences, University of California, Irvine, Irvine, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5490-2427
  10. Timothy Bredy

    Queensland Brain Institute, University of Queensland, Brisbane, Australia
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3280-126X
  11. Marcelo A Wood

    Department of Neurobiology and Behavior, University of California, Irvine, Irvine, United States
    For correspondence
    mwood@uci.edu
    Competing interests
    No competing interests declared.
  12. Andrej Luptak

    Department of Pharmaceutical Sciences, University of California, Irvine, Irvine, United States
    For correspondence
    aluptak@uci.edu
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0632-5442

Funding

National Institutes of Health (R01AG051807)

  • Marcelo A Wood

National Institutes of Health (RF1AG057558)

  • Marcelo A Wood

National Science Foundation (1804220)

  • Andrej Luptak

National Science Foundation (1330606)

  • Andrej Luptak

National Science Foundation Graduate Research Fellowship Program

  • Claire C Chen

National Institutes of Health (R01CA229696)

  • Claire C Chen

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Anne E West, Duke University, United States

Ethics

Animal experimentation: All experimental procedures were performed according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee of the University of California, Irvine.

Version history

  1. Preprint posted: June 9, 2023 (view preprint)
  2. Received: June 13, 2023
  3. Accepted: February 5, 2024
  4. Accepted Manuscript published: February 6, 2024 (version 1)
  5. Version of Record published: March 7, 2024 (version 2)

Copyright

© 2024, Chen et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 551
    views
  • 89
    downloads
  • 0
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Claire C Chen
  2. Joseph Han
  3. Carlene A Chinn
  4. Jacob S Rounds
  5. Xiang Li
  6. Mehran Nikan
  7. Marie Myszka
  8. Liqi Tong
  9. Luiz F M Passalacqua
  10. Timothy Bredy
  11. Marcelo A Wood
  12. Andrej Luptak
(2024)
Inhibition of Cpeb3 ribozyme elevates CPEB3 protein expression and polyadenylation of its target mRNAs, and enhances object location memory
eLife 13:e90116.
https://doi.org/10.7554/eLife.90116

Share this article

https://doi.org/10.7554/eLife.90116

Further reading

    1. Chromosomes and Gene Expression
    Rupam Choudhury, Anuroop Venkateswaran Venkatasubramani ... Axel Imhof
    Research Article

    Eukaryotic chromatin is organized into functional domains, that are characterized by distinct proteomic compositions and specific nuclear positions. In contrast to cellular organelles surrounded by lipid membranes, the composition of distinct chromatin domains is rather ill described and highly dynamic. To gain molecular insight into these domains and explore their composition, we developed an antibody-based proximity-biotinylation method targeting the RNA and proteins constituents. The method that we termed Antibody-Mediated-Proximity-Labelling-coupled to Mass Spectrometry (AMPL-MS) does not require the expression of fusion proteins and therefore constitutes a versatile and very sensitive method to characterize the composition of chromatin domains based on specific signature proteins or histone modifications. To demonstrate the utility of our approach we used AMPL-MS to characterize the molecular features of the chromocenter as well as the chromosome territory containing the hyperactive X-chromosome in Drosophila. This analysis identified a number of known RNA binding proteins in proximity of the hyperactive X and the centromere, supporting the accuracy of our method. In addition, it enabled us to characterize the role of RNA in the formation of these nuclear bodies. Furthermore, our method identified a new set of RNA molecules associated with the Drosophila centromere. Characterization of these novel molecules suggested the formation of R-loops in centromeres, which we validated using a novel probe for R-loops in Drosophila. Taken together, AMPL-MS improves the selectivity and specificity of proximity ligation allowing for novel discoveries of weak protein-RNA interactions in biologically diverse domains.

    1. Cancer Biology
    2. Chromosomes and Gene Expression
    Gregory Caleb Howard, Jing Wang ... William P Tansey
    Research Article

    The chromatin-associated protein WD Repeat Domain 5 (WDR5) is a promising target for cancer drug discovery, with most efforts blocking an arginine-binding cavity on the protein called the ‘WIN’ site that tethers WDR5 to chromatin. WIN site inhibitors (WINi) are active against multiple cancer cell types in vitro, the most notable of which are those derived from MLL-rearranged (MLLr) leukemias. Peptidomimetic WINi were originally proposed to inhibit MLLr cells via dysregulation of genes connected to hematopoietic stem cell expansion. Our discovery and interrogation of small-molecule WINi, however, revealed that they act in MLLr cell lines to suppress ribosome protein gene (RPG) transcription, induce nucleolar stress, and activate p53. Because there is no precedent for an anticancer strategy that specifically targets RPG expression, we took an integrated multi-omics approach to further interrogate the mechanism of action of WINi in human MLLr cancer cells. We show that WINi induce depletion of the stock of ribosomes, accompanied by a broad yet modest translational choke and changes in alternative mRNA splicing that inactivate the p53 antagonist MDM4. We also show that WINi are synergistic with agents including venetoclax and BET-bromodomain inhibitors. Together, these studies reinforce the concept that WINi are a novel type of ribosome-directed anticancer therapy and provide a resource to support their clinical implementation in MLLr leukemias and other malignancies.